Warrior Met Coal CEO Sells 50,000 Shares for $5.5 Million
Walter J. Scheller sold 50,000 shares for $5.5 million on August 24, 2026. The transaction size was equal to 16% of the equity held prior to the disposal.
HCC - Warrior Met Coal, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$100.00
DETAILS
HIGH:
$100.00
LOW:
$100.00
MEDIAN:
$100.00
CONSENSUS:
$100.00
DOWNSIDE:
6.60%
Stock News
131,115 Shares in Warrior Met Coal $HCC Acquired by Deutsche Bank AG
Deutsche Bank AG purchased a new stake in Warrior Met Coal (NYSE: HCC) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 131,115 shares of the company's stock, valued at approximately $10,641,000. Deutsche Bank AG owned 0.25% of Warrior
Is Warrior Met Coal Inc (HCC) Overvalued After 3.3% Rally? GF Value Says Overvalued
On August 21, 2026, Warrior Met Coal Inc (HCC) shares rose by 3.3% to a current price of $106.73, reflecting strong momentum over recent weeks. The stock has ex
Mohnish Pabrai's Top Q2 2026 Move: Trimming Alpha Metallurgical Resources Inc at a -3.04% Portfolio Impact
Insights from the Pabrai Investment Funds 13F Filing for the Second Quarter of 2026Mohnish Pabrai (Trades, Portfolio), the Managing Partner of Pabrai Investment
Warrior Met Coal Q2 Earnings Call Highlights
Warrior Met Coal NYSE: HCC reported sharply higher second-quarter earnings and cash generation as its Blue Creek mine contributed additional sales volumes and lower-cost production, while management raised its full-year sales and production outlook.
Warrior Met Coal, Inc. (HCC) Q2 2026 Earnings Call Transcript
Warrior Met Coal, Inc. (HCC) Q2 2026 Earnings Call Transcript
Warrior Met Coal (HCC) Surpasses Q2 Earnings and Revenue Estimates
Warrior Met Coal (HCC) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $0.11 per share a year ago.
Warrior Reports Second Quarter 2026 Results
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the second quarter of 2026. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry. Warrior reported net income for the second quarter of 2026 of $87.4 million, or $1.65 per diluted share, an increase from net income of $5.6 million, or $0.11 per diluted share, in the second quarter of 2025. Adjust.
Warrior Met Coal (HCC) Earnings Expected to Grow: Should You Buy?
Warrior Met Coal (HCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Warrior Announces Regular Quarterly Cash Dividend
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08 per share to be paid on August 17, 2026, to stockholders of record as of the close of business on August 10, 2026.About WarriorWarrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal use.
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan
Fifth Third Bancorp Has $1.12 Million Stock Position in Warrior Met Coal $HCC
Fifth Third Bancorp grew its stake in shares of Warrior Met Coal (NYSE: HCC) by 4,036.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 12,037 shares of the company's stock after purchasing an additional 11,746 shares during the period. Fifth Third Bancorp's holdings in
Warrior Sets Date for Second Quarter 2026 Earnings Announcement and Investor Conference Call
BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its second quarter 2026 investor conference call at 4:30 p.m. ET on Wednesday, August 5, 2026. Warrior will release its results following the close of market trading that afternoon. To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A w.
HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Pursue Nasdaq Listing
Transaction expected to provide HCC Healthcare with access to public capital markets to accelerate growth in integrated medical and long-term care services across Asia Transaction expected to provide HCC Healthcare with access to public capital markets to accelerate growth in integrated medical and long-term care services across Asia
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational i
Warrior Met Coal Inc (HCC) Shares Fall 4.3% -- What GF Score of 81 Tells Investors
On June 09, 2026, Warrior Met Coal Inc (HCC) shares fell 4.3% to a current price of $94.67, continuing a downward trend noted over the past week with a decline
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
This $4 Million Warrior Met Coal Sale May Be More About Profit Taking Than Coal Prices
Warrior Met Coal supplies high-grade metallurgical coal to global steelmakers, leveraging underground mining operations in Alabama.
Price Targets
Warrior Met Coal price target lowered to $100 from $102 at UBS
$100.00
(was $81.57)
UBS
Warrior Met Coal price target raised to $105 from $101 at UBS
$105.00
(was $99.16)
George Eadie
·
UBS
Warrior Met Coal upgraded to Buy from Neutral at UBS
$108.00
(was $90.09)
UBS
Warrior Met Coal price target raised to $120 from $95 at Jefferies
$120.00
(was $99.27)
Jefferies
Warrior Met Coal price target raised to $86 from $80 at UBS
$86.00
(was $82.46)
George Eadie
·
UBS
Warrior Met Coal price target raised to $80 from $75 at UBS
$80.00
(was $75.07)
UBS
Warrior Met Coal price target raised to $68 from $60 at UBS
$68.00
(was $63.88)
UBS
Warrior Met Coal (HCC) PT Raised to $55 at BMO Capital
$55.00
(was $58.73)
Katja Jancic
·
BMO Capital
Warrior Met Coal downgraded to Market Perform from Outperform at BMO Capital
$37.00
(was $31.52)
David Gagliano
·
BMO Capital